These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 20493518)

  • 1. Increasing medical staff safety by using a closed system for intravesical instillation of mitomycin C.
    Haifler M; Lang E; Sabler I; Gutman Y; Lindner A; Zisman A
    Urology; 2010 Sep; 76(3):649-51. PubMed ID: 20493518
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Contemporary cost analysis of single instillation of mitomycin after transurethral resection of bladder tumor in a universal health care system.
    Feifer A; Xie X; Brophy JM; Segal R; Kassouf W
    Urology; 2010 Sep; 76(3):652-6. PubMed ID: 20394970
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics of intravesical mitomycin C in superficial bladder cancer patients.
    Dalton JT; Wientjes MG; Badalament RA; Drago JR; Au JL
    Cancer Res; 1991 Oct; 51(19):5144-52. PubMed ID: 1913640
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Early postoperative mitomycin C instillation: when and how?].
    Traxer O; Gattegno B
    Prog Urol; 2004 Apr; 14(2):249-51. PubMed ID: 15217151
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immediate administration of intravesical mitomycin C after tumour resection for superficial bladder cancer.
    Mostafid AH; Rajkumar RG; Stewart AB; Singh R
    BJU Int; 2006 Mar; 97(3):509-12. PubMed ID: 16469017
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effect of repeat transurethral resection on recurrence and progression rates in patients with T1 tumors of the bladder who received intravesical mitomycin: a prospective, randomized clinical trial.
    Divrik RT; Yildirim U; Zorlu F; Ozen H
    J Urol; 2006 May; 175(5):1641-4. PubMed ID: 16600720
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Single instillation of mitomycin C reduces 1st year recurrence following transurethral resection of non-muscle invasive bladder cancer.
    Ather MH; Aziz S; Sulaiman MN
    J Ayub Med Coll Abbottabad; 2007; 19(4):18-20. PubMed ID: 18693589
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Risk of post-operative intravesical mitomycin C instillation following transurethral bladder tumor resection.
    Shapiro O; Jones K; Wang C; Landas S; Haas GP
    Can J Urol; 2006 Dec; 13(6):3317-20. PubMed ID: 17187694
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Increasing patient comfort by optimized postoperative administration of intravesical mitomycin C.
    Stoehr B; Mueller T; Granig T; Zangerl F; Steiner H
    BJU Int; 2008 Dec; 102(11):1556-9. PubMed ID: 18691179
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Lung sarcoidosis following instillation of mitomycin C in the urinary bladder].
    Cuervo Pinna MA; Cuervo Pinna C; Macías Castillo S; Bureo Dacal JC; Espada Alonso MJ; Pimentel Leo J
    An Med Interna; 2001 Dec; 18(12):641-3. PubMed ID: 11852501
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intravesical electromotive mitomycin C versus passive transport mitomycin C for high risk superficial bladder cancer: a prospective randomized study.
    Di Stasi SM; Giannantoni A; Stephen RL; Capelli G; Navarra P; Massoud R; Vespasiani G
    J Urol; 2003 Sep; 170(3):777-82. PubMed ID: 12913696
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Drug eruption due to intravesical instillations of both epirubicin and mitomycin C.
    Okumura A; Oishi N; Kaji K; Imamura T; Fuse H
    J Dermatol; 2009 Jul; 36(7):419-22. PubMed ID: 19583691
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intravesical mitomycin C for superficial transitional cell carcinoma.
    Bolenz C; Cao Y; Arancibia MF; Trojan L; Alken P; Michel MS
    Expert Rev Anticancer Ther; 2006 Aug; 6(8):1273-82. PubMed ID: 16925493
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Systemic absorption and pharmacokinetics of single-dose early intravesical mitomycin C after transurethral resection of non-muscle-invasive bladder cancer.
    Maffezzini M; Campodonico F; Manuputty EE; Puntoni M; Martelli A; Marini V; Tamagno S; Mattioli F
    Urology; 2013 Aug; 82(2):400-4. PubMed ID: 23791221
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Perivesical inflammation and necrosis due to mitomycin C instillation after transurethral resection of bladder tumor: we must be vigilant!
    Fazlioglu A; Tandogdu Z; Kurtulus FO; Parlakkilic O; Cek M
    Urol Int; 2009; 83(3):362-3. PubMed ID: 19829042
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An individual patient data meta-analysis of the long-term outcome of randomised studies comparing intravesical mitomycin C versus bacillus Calmette-Guérin for non-muscle-invasive bladder cancer.
    Malmström PU; Sylvester RJ; Crawford DE; Friedrich M; Krege S; Rintala E; Solsona E; Di Stasi SM; Witjes JA
    Eur Urol; 2009 Aug; 56(2):247-56. PubMed ID: 19409692
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Management of non invasive bladder cancers. T1Ga urothelial cell carcinoma: benefit of immediate post operative instillation?].
    Rouprêt M; Guillotreau J; Irani J; Zerbib M
    Prog Urol; 2010 Mar; 20 Suppl 1():S46-9. PubMed ID: 20493444
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intravesical bacille Calmette-Guérin versus mitomycin C in superficial bladder cancer: formal meta-analysis of comparative studies on tumor progression.
    Böhle A; Bock PR
    Urology; 2004 Apr; 63(4):682-6; discussion 686-7. PubMed ID: 15072879
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Practical impact of pharmacologic and clinical data on early post-operative instillation of mitomycin C].
    Bonnal JL
    Prog Urol; 2002 Feb; 12(1):118-23. PubMed ID: 11980004
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Immediate post TURBT MMC instillation.].
    Domínguez-Escrig JL
    Arch Esp Urol; 2018 May; 71(4):376-383. PubMed ID: 29745926
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.